M&A Deal Summary

Pfizer Acquires Seagen

On March 13, 2023, Pfizer acquired life science company Seagen for 43.0B USD

Acquisition Highlights
  • This is Pfizer’s 39th transaction in the Life Science sector.
  • This is Pfizer’s 4th largest (disclosed) transaction.
  • This is Pfizer’s 31st transaction in the United States.
  • This is Pfizer’s 1st transaction in Washington.

M&A Deal Summary
Date 2023-03-13
Target Seagen
Sector Life Science
Buyer(s) Pfizer
Deal Type Add-on Acquisition
Deal Value 43.0B USD
Advisor(s) Centerview Partners
MTS Health Partners LP (Financial)
Sullivan & Cromwell (Legal)

Target

Seagen

Bothell, Washington, United States
Seagen is a biotechnology company provides an antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. Seattle was founded in 1997 and is based in Bothell, Washington.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States
Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 43 of 43
Sector (Life Science) 39 of 39
Type (Add-on Acquisition) 31 of 31
State (Washington) 1 of 1
Country (United States) 31 of 31
Year (2023) 1 of 1
Size (of disclosed) 4 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-08 GBT

San Francisco, California, United States

GBT is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor.

Buy $5.4B
Mergr

Product

Company

Legal